SAN DIEGO, Feb. 25, 2014 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (NASDAQ:NBIX) today announced that two NBI-98854
scientific abstracts have been accepted for the scientific program
at the 2014 Annual Congress of Parkinson's Disease and Movement
Disorders, to be held June 8-12, 2014
in Stockholm Sweden. This annual
meeting draws over 5,000 experts from around the world to address
current topics related to movement disorders.
"We are very pleased to participate in the Annual Congress
of Parkinson's Disease and Movement Disorders," said
Chris O'Brien, M.D., Chief Medical
Officer at Neurocrine. "This is the most important meeting for
movement disorders that brings together clinicians and scientists
from around the globe. Having abstracts for both Kinect 1 and
Kinect 2 accepted for presentation at this prestigious meeting
allows us to share the breadth of our tardive dyskinesia clinical
efforts during the congress."
An abstract from the Kinect 1 study of
NBI-98854 for the treatment of tardive dyskinesia entitled
"Kinect 1 Extension: 12-week treatment of Tardive
Dyskinesia with NBI-98854" and an abstract of the Kinect 2
study of NBI-98854 entitled "Kinect 2: NBI-98854 Treatment of
Moderate to Severe Tardive Dyskinesia" are scheduled to be
presented by the Company on June 11,
2014 in Stockholm.
Both of these abstracts will describe the methodology of each
clinical trial, safety and efficacy results, and statistical
findings along with key clinical observations.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc. discovers and develops innovative
and life-changing pharmaceuticals, in diseases with high unmet
medical needs, through its novel R&D platform, focused on
neurological and endocrine based diseases and disorders. The
Company's two lead late-stage clinical programs are elagolix, a
gonadotropin-releasing hormone antagonist for women's health that
is partnered with AbbVie Inc., and a wholly owned vesicular
monoamine transporter 2 inhibitor for the treatment of movement
disorders. Neurocrine intends to maintain certain commercial rights
to its VMAT2 inhibitor for evolution into a fully-integrated
pharmaceutical company.
Neurocrine Biosciences, Inc. news releases are available through
the Company's website via the internet at
http://www.neurocrine.com.
In addition to historical facts, this press release may
contain forward-looking statements that involve a number of risks
and uncertainties. Among the factors that could cause actual
results to differ materially from those indicated in the
forward-looking statements are risks and uncertainties associated
with Neurocrine's business and finances in general, and Company
overall. In addition, the Company faces risks and uncertainties
with respect to the Company's R & D pipeline including risk
that the Company's clinical candidates will not be found to be safe
and effective; and the other risks described in the Company's
report on Form 10-K for the year ended December 31, 2013. Neurocrine undertakes no
obligation to update the statements contained in this press release
after the date hereof.
SOURCE Neurocrine Biosciences, Inc.